Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
Stopped early · Not applicable
Conditions studied: Brain Metastases
In brief
This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control. The WBRT dose would decrease as the study moves forward, both in terms of absolute value and equivalent dose in 2 Gray fractions (EQD2) (as determined by the linear quadratic radiobiological model). The absolute value of the simultaneous integrated boost (SIB) dose will change with each dose level because the number of fractions delivered will depend on the WBRT dose. As such, the SIB dose will be manipulated such that the EQD2 will remain essentially equivalent despite the difference in the number of fractions delivered. This design will ensure that the only variable is the change in WBRT dose. The concept is that WBRT with SIB would be expected to maximize both local and in-brain distant control as has already been shown in studies exploring WBRT with SRS boost. However, by itself WBRT with SIB does not address the concern over neurocognitive outcomes. Therefore, investigators hypothesize that there is a lower WBRT dose threshold that will maintain acceptable in-brain distant control, particularly in the setting of a SIB to gross lesions to maintain treated lesion control. In addition, lower overall brain dose (including lower hippocampal dose without specific hippocampal avoidance) may potentially improve neurocognitive function. Investigators are also interested in evaluating treated lesion control, overall survival, neurocognitive sequelae of therapy, quality of life, performance status, and adverse effects of therapy. Biomarker identification for potential correlative circulating tumor DNA and microRNA is an exploratory endpoint to generate data for future prospective evaluation.
Key facts
- Study ID
- NCT03189381
- Run by
- Indiana University
- People needed
- 20
- Starts
- 2017-09-21
- Expected to finish
- 2022-09-30
- Last updated by the study team
- 2024-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 at time of consent.
- Ability to provide written informed consent and HIPAA authorization.
- Pathological diagnosis of any solid tumor histology (from any site in the body).
- Pathological or clinical (i.e., by imaging) diagnosis of brain metastatic tumor lesions.
- Total volume of lesions ≤ 30 cm3.
- Maximum volume of largest lesion ≤ 5 cm3.
- a. This volume limit would be equivalent to a largest diameter of about 2.1 cm, assuming a perfect sphere.
- Not a candidate for or eligible for but refused Gamma Knife radiosurgery.
You may not qualify if…
- Previous radiation to the brain, including WBRT or brain radiosurgery.
- Life expectancy < 6 months (as estimated per current ds-GPA).
- For histologies not included in the ds-GPA publications or otherwise noted online at brainmetgpa.com, the PI will use either published or validated data, or the PI's best clinical judgment to determine the patient's expected survival.
- Inability to comply with treatment per investigator discretion.
- Inability to complete neurocognitive assessments per investigator discretion.
- Of note, tumor lesion number is not an inclusion or exclusion criteria as we are using volume-based criteria instead.
Where it is running
- Indiana University Health Hospital — Indianapolis, Indiana, United States
- Indiana University Health Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Methodist Hospital — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.